Want to join the conversation?
$KO 2Q15 PR: Apart from North America, all other segment’s net operating revenue declined YoverY. Gross profit was $7.408Bil vs. $7.755Bil in 2Q14. YTD net share repurchases totalled $876MM and company expects full-year 2015 net share repurchases of $2-2.5Bil. Company had cash and cash equivalents of $8,805MM vs. $11,618MM in 2Q14.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.